PDS STUDY ON HUMAN PGP MDR TRANSPORTER ABCB1
人类 PGP MDR 转运蛋白 ABCB1 的 PDS 研究
基本信息
- 批准号:8172217
- 负责人:
- 金额:$ 1.54万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2010
- 资助国家:美国
- 起止时间:2010-09-01 至 2011-08-31
- 项目状态:已结题
- 来源:
- 关键词:ABCB1 geneATP-Binding Cassette TransportersAnthracyclinesBrainCell membraneCellsChemicalsColonComputer Retrieval of Information on Scientific Projects DatabaseCytotoxic agentD CellsDactinomycinDeerDrug InteractionsDrug KineticsExcretory functionExhibitsExposure toFundingGlycoproteinsGrantHeat-Shock ResponseHumanInstitutionIntestinesKidneyLiverMediatingMetabolismMulti-Drug ResistanceNormal tissue morphologyP-GlycoproteinP-GlycoproteinsPaclitaxelPharmaceutical PreparationsPhenotypePhysiologicalPlayProcessResearchResearch PersonnelResistanceResourcesRoentgen RaysRoleSmall IntestinesSourceStressTaxoidsToxic effectUltraviolet RaysUnited States National Institutes of HealthVinca AlkaloidsXenobioticsabsorptioncancer celldrug marketinhibitor/antagonistirradiationtumor
项目摘要
This subproject is one of many research subprojects utilizing the
resources provided by a Center grant funded by NIH/NCRR. The subproject and
investigator (PI) may have received primary funding from another NIH source,
and thus could be represented in other CRISP entries. The institution listed is
for the Center, which is not necessarily the institution for the investigator.
P-glycoprotein (Pgp, ABCB1), which belongs to the ATP-binding cassette (ABC) transporter superfamily, is a mammalian plasma membrane phospho-glycoprotein encoded by the multidrug resistance 1 (MDR1) gene. Pgp plays a role in the resistance of tumors to cytotoxic drugs and is known to efflux structurally unrelated diverse amphipathic compounds from cells. Pgp is expressed both in multidrug-resistant cancer cells and also in a number of normal tissues, such as those of the liver, kidney, small intestine, colon, and brain, suggesting that the physiological role of Pgp is a protective mechanism against xenobiotics and endogenous metabolites. After exposure to a single cytotoxic drug such as one of the Vinca alkaloids, anthracyclines, taxoids, or actinomycin D, cells can over-express Pgp and exhibit the MDR phenotype. Pgp over-expression is induced not only by chemical compounds, but also by physical stress caused by X-rays and ultraviolet light irradiation, or heat shock. Approximately 50% of currently marketed drugs have been identified to be Pgp substrates and/or inhibitors. Pgp can influence the pharmacokinetics of drugs by contributing to the processes that govern absorption, distribution, metabolism, elimination, and/or toxicity (ADMET). Additionally, Pgp has been implicated in drug-drug interactions involving co-administered Pgp substrates and modulators. For instance, intestinal Pgp mediates substantial direct transepithelial excretion of drugs including paclitaxel. ABCB1 is not oligomeric, but is homologous to dimeric prokaryotic ABC transporters, such as MsbA, which has been successfully studied at ACERT by Ku-band DEER.
该副本是利用众多研究子项目之一
由NIH/NCRR资助的中心赠款提供的资源。子弹和
调查员(PI)可能已经从其他NIH来源获得了主要资金,
因此可以在其他清晰的条目中代表。列出的机构是
对于中心,这不一定是调查员的机构。
属于ATP结合盒(ABC)转运蛋白超家族的P-糖蛋白(PGP,ABCB1)是由多种耐药性1(MDR1)基因编码的哺乳动物质膜磷酸 - 糖蛋白。 PGP在肿瘤对细胞毒性药物的耐药性中起作用,并已知从细胞结构上无关的多种两亲性化合物中排出。 PGP在多药耐药性癌细胞中均表达,以及许多正常组织,例如肝脏,肾脏,小肠,结肠和大脑的组织,这表明PGP的生理作用是针对异种生物和内源代谢物的保护机制。接触到单一细胞毒性药物(例如VINCA生物碱,蒽环类药物,紫菜素或放线肌蛋白D),细胞可以过表达PGP并表现出MDR表型。 PGP过表达不仅是由化合物引起的,而且还由X射线和紫外线光照射或热休克引起的身体应力引起。目前大约有50%的销售药物被确定为PGP底物和/或抑制剂。 PGP可以通过为控制吸收,分布,代谢,消除和/或毒性的过程做出贡献(ADMET)来影响药物的药代动力学。此外,PGP与涉及共同管理PGP底物和调节剂的药物相互作用有关。例如,肠道PGP介导了包括紫杉醇在内的药物的实质性直接直接旋转。 ABCB1不是低聚物,而是与二聚体原核ABC转运蛋白(例如MSBA)同源的,该转运蛋白已由KU波段鹿成功地在ACERT上进行了研究。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
PETER P BORBAT其他文献
PETER P BORBAT的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('PETER P BORBAT', 18)}}的其他基金
STUDY OF PROTEIN DYNAMICS UNDER HIGH HYDROSTATIC PRESSURE
高静水压下蛋白质动力学的研究
- 批准号:
8364112 - 财政年份:2011
- 资助金额:
$ 1.54万 - 项目类别:
PULSE DIPOLAR ESR STUDY ON INTERACTION OF HIV-1 NUCLEOCAPSID PROTEIN NCP7
HIV-1 核衣壳蛋白 NCP7 相互作用的脉冲偶极 ESR 研究
- 批准号:
8364052 - 财政年份:2011
- 资助金额:
$ 1.54万 - 项目类别:
INCREASING SENSITIVITY OF PULSE SPECTROMETER BY OPTIMIZING THE PROBE-HEAD DESIGN
通过优化探头设计提高脉冲光谱仪的灵敏度
- 批准号:
8364077 - 财政年份:2011
- 资助金额:
$ 1.54万 - 项目类别:
SPECTROMETER FOR TIME-RESOLVED 2D-FT ESR
用于时间分辨 2D-FT ESR 的光谱仪
- 批准号:
8364110 - 财政年份:2011
- 资助金额:
$ 1.54万 - 项目类别:
DEVELOPMENT OF HIGH-THROUGHPUT PULSE DIPOLAR ESR SPECTROSCOPY (HT-PDS)
高通量脉冲偶极 ESR 光谱 (HT-PDS) 的开发
- 批准号:
8364075 - 财政年份:2011
- 资助金额:
$ 1.54万 - 项目类别:
AUTOMATION OF DATA ACQUISITION TO HANDLE SEVERAL SAMPLES SIMULTANEOUSLY
数据采集自动化以同时处理多个样本
- 批准号:
8364080 - 财政年份:2011
- 资助金额:
$ 1.54万 - 项目类别:
相似国自然基金
基于超声多模态评价技术探讨肝脏靶向递送ABCA1新策略在动脉粥样硬化防治中的应用
- 批准号:81871357
- 批准年份:2018
- 资助金额:57.0 万元
- 项目类别:面上项目
基于SIRT1-LXR通路的化合物E4023抗动脉粥样硬化的作用及机制研究
- 批准号:81703503
- 批准年份:2017
- 资助金额:20.0 万元
- 项目类别:青年科学基金项目
基于LXRα-SREBP1-ABCA1/G1信号通路的益气活血化痰方调脂抗动脉粥样硬化机制研究
- 批准号:81774088
- 批准年份:2017
- 资助金额:55.0 万元
- 项目类别:面上项目
肝脏X受体激动剂干预β淀粉样蛋白诱导的视网膜炎性反应的作用及机制
- 批准号:81670881
- 批准年份:2016
- 资助金额:51.0 万元
- 项目类别:面上项目
新型ABCA1上调剂E17241改善糖脂代谢紊乱的机制研究
- 批准号:81573482
- 批准年份:2015
- 资助金额:50.0 万元
- 项目类别:面上项目
相似海外基金
PDS STUDY ON HUMAN PGP MDR TRANSPORTER ABCB1
人类 PGP MDR 转运蛋白 ABCB1 的 PDS 研究
- 批准号:
8364053 - 财政年份:2011
- 资助金额:
$ 1.54万 - 项目类别:
PDS STUDY ON HUMAN PGP MDR TRANSPORTER ABCB1
人类 PGP MDR 转运蛋白 ABCB1 的 PDS 研究
- 批准号:
7956743 - 财政年份:2009
- 资助金额:
$ 1.54万 - 项目类别: